These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1142 related items for PubMed ID: 28060446

  • 1. Successful treatment of donor-derived hepatitis C viral infection in three transplant recipients from a donor at increased risk for bloodborne pathogens.
    Shah AP, Cameron A, Singh P, Frank AM, Fenkel JM.
    Transpl Infect Dis; 2017 Apr; 19(2):. PubMed ID: 28060446
    [Abstract] [Full Text] [Related]

  • 2. Persistence of Virologic Response after Liver Transplant in Hepatitis C Patients Treated with Ledipasvir / Sofosbuvir Plus Ribavirin Pretransplant.
    Yoshida EM, Kwo P, Agarwal K, Duvoux C, Durand F, Peck-Radosavljevic M, Lilly L, Willems B, Vargas H, Kumar P, Brown RS, Horsmans Y, De-Oertel S, Arterburn S, Dvory-Sobol H, Brainard DM, McHutchison JG, Terrault N, Rizzetto M, Müllhaupt B.
    Ann Hepatol; 2017 Apr; 16(3):375-381. PubMed ID: 28425407
    [Abstract] [Full Text] [Related]

  • 3. Use of a hepatitis C virus (HCV) RNA-positive donor in a treated HCV RNA-negative liver transplant recipient.
    Campos-Varela I, Agudelo EZ, Sarkar M, Roberts JP, Terrault NA.
    Transpl Infect Dis; 2018 Feb; 20(1):. PubMed ID: 29125670
    [Abstract] [Full Text] [Related]

  • 4. Successful treatment of donor-derived hepatitis C infection in a lung transplant recipient.
    Theodoropoulos N, Whitson BA, Martin SI, Pouch S, Pope-Harman A.
    Transpl Infect Dis; 2017 Apr; 19(2):. PubMed ID: 28060441
    [Abstract] [Full Text] [Related]

  • 5. Treatment of HCV infection in liver transplant recipients with ledipasvir and sofosbuvir without ribavirin.
    Pillai AA, Maheshwari R, Vora R, Norvell JP, Ford R, Parekh S, Cheng N, Patel A, Young N, Spivey JR, Mgbemena O, Wedd JP.
    Aliment Pharmacol Ther; 2017 Jun; 45(11):1427-1432. PubMed ID: 28382751
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and Safety of Direct Acting Antivirals in Kidney Transplant Recipients with Chronic Hepatitis C Virus Infection.
    Lin MV, Sise ME, Pavlakis M, Amundsen BM, Chute D, Rutherford AE, Chung RT, Curry MP, Hanifi JM, Gabardi S, Chandraker A, Heher EC, Elias N, Riella LV.
    PLoS One; 2016 Jun; 11(7):e0158431. PubMed ID: 27415632
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Sofosbuvir plus ledispasvir for recurrent hepatitis C in liver transplant recipients.
    Kwok RM, Ahn J, Schiano TD, Te HS, Potosky DR, Tierney A, Satoskar R, Robertazzi S, Rodigas C, Lee Sang M, Wiegel J, Patel N, Gripshover J, Hassan MA, Branch A, Smith CI.
    Liver Transpl; 2016 Nov; 22(11):1536-1543. PubMed ID: 27543748
    [Abstract] [Full Text] [Related]

  • 11. Successful treatment of chronic hepatitis C infection with directly acting antivirals in renal transplant recipients.
    Taneja S, Duseja A, De A, Kumar V, Ramachandran R, Sharma A, Dhiman RK, Gupta KL, Chawla Y.
    Nephrology (Carlton); 2018 Sep; 23(9):876-882. PubMed ID: 28703905
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 58.